The use of plasma rather than serum for determination of cardiac troponins can improve turnaround time and potentially avoid incomplete serum separation that may produce falsely increased results. We investigated the influence of incomplete serum separation and the effect of heparin-plasma on cardiac troponin concentrations. Methods: Serum and heparin-plasma samples were drawn simultaneously from 100 patients (50 patients with acute coronary syndrome and 50 patients after open heart surgery) and measured on three different analytical systems, two for determination of cardiac troponin I (cTnI; Abbott AxSYM and Bayer ACS:Centaur) and one for cardiac troponin T (cTnT; Roche Elecsys cTnT STAT). Serum samples were reanalyzed after a second centrifugation to assess the influence of incomplete serum separation. Results: Mean results (؎ 95% confidence interval) in heparin-plasma compared with serum were 101% ؎ 2% (AxSYM cTnI), 94% ؎ 3% (ACS:Centaur cTnI), and 99% ؎ 3% (Elecsys cTnT). Differences >20% were seen in 11% of results on the ACS:Centaur, 9% of results on Elecsys cTnT, and 2% of results on the AxSYM. For the Elecsys cTnT assay, the magnitude of the difference between serum and plasma was independent of the absolute concentration and confined to individual samples, and was reversed by treatment with heparinase. A second centrifugation had no effect on serum results by any of the assays.
For determination of cardiac troponins, many laboratories prefer plasma rather than serum. Among the reasons for this are expedition of turnaround time and concerns that incomplete separation of serum, especially in a high-risk population receiving anticoagulant therapy, may produce falsely increased cardiac troponin I (cTnI) 4 results (1 ) . The National Academy of Clinical Biochemistry has recommended the use of plasma as the specimen of choice for the stat analysis of cardiac markers (2 ) . Nevertheless, some assay systems come with the limitation that plasma anticoagulated with heparin, sodium citrate, or EDTA cannot be used because of random or systematic deviations (3 ) .
A recent study by Gerhardt et al. (4 ) published in this journal demonstrated that results for cardiac troponin T (cTnT) are 15% lower in heparin-plasma than in serum. On the basis of these results, Roche Diagnostics, manufacturer of the cTnT assay, advised customers not to use heparin-plasma in their assay. Many laboratories have relied on heparin-plasma for determination of cTnT, and several clinical studies, including the recently published PRISM study (5 ) , were conducted with heparin-plasma. Because at our central laboratory heparin-plasma as well as serum is used routinely for determination of cardiac troponins, we investigated the influence of incomplete serum separation and of heparin-plasma on cardiac troponin concentrations in three common analytical test systems under routine conditions.
Materials and Methods patients
Blood was collected from 50 patients with suspected or already diagnosed acute coronary syndrome (35 males and 15 females; age range, 48 -83 years) and 50 patients on the second or third postoperative day after elective open heart surgery (41 males and 9 females; age range, 50 -71 years). At the time of phlebotomy all patients received oral, intravenous, or subcutaneous anticoagulant therapy that included phenprocoumon, heparin, or lowmolecular weight heparin.
All patients gave informed consent. Results were not reported to the primary care physicians and therefore had no influence on the diagnostic work-up or clinical decisions.
blood sampling and sample handling
The study design is shown in Fig. 1 . Briefly, venous blood was collected after phlebotomy simultaneously into serum separator tubes (cat. no. 04.1935; Sarstedt) and lithium heparinate tubes (15 IU/mL of whole blood; ϳ25 IU/mL of plasma based on a hematocrit of 0.40; cat. no. 01.1608.001; Sarstedt). Immediately after collection, sampling tubes were gently mixed by inverting the tubes five to eight times. Within 10 -15 min after venipuncture, both tubes were centrifuged at 3000g for 10 min. After centrifugation, both the serum and the heparin-plasma were divided into three aliquots of 500 L and measured immediately on all three analytical systems. After initial measurements for cTnI and cTnT, the serum aliquots underwent a second centrifugation at 3000g for 10 min and were remeasured to assess the influence of incomplete serum separation.
For measurement of the activated partial thromboplastin time (aPTT), blood was collected into tubes containing sodium citrate as the anticoagulant (cat. no. 05.1071.001; Sarstedt). determination of cTnI and cTnT All samples were assayed within 1 h after collection. cTnI was measured by a two-step microparticle enzyme immunoassay on the AxSYM analyzer (Abbott Laboratories, Abbott Park, IL) as well as by an acridinium ester-based two-step chemiluminescence immunoassay on the ACS: Centaur analyzer (Bayer Diagnostics, Tarrytown, NY). cTnT was measured by a third-generation electrochemiluminescence immunoassay on the Elecsys 1010 analyzer (Roche Diagnostics, Mannheim, Germany). All assays were performed according to the manufacturers' instructions. Results Ͼ50 g/L on the AxSYM and ACS:Centaur were retested after a 10-fold internal dilution. No tested sample was found to be above the measuring range of the Elecsys assay.
The clinical cutoff values for acute myocardial infarction, as stated by the manufacturers in their respective reagent packages, are 2.0 g/L for the Abbott AxSYM cTnI assay, 1.5 g/L for the Bayer ACS:Centaur cTnI assay, and 0.1 g/L for the Roche Elecsys cTnT assay.
analytical performance
Three different concentrations for serum as well as for plasma were prepared by diluting patient serum or plasma samples containing high cardiac troponin concentrations with cTnI-and cTnT-negative serum or plasma pools. Aliquots of each concentration were frozen at Ϫ70°C and were thawed immediately before analysis. For determination of within-run imprecision, all three concentrations were analyzed 21 times in one analytical run. For determination of between-day imprecision, all three concentrations were analyzed in 11 analytical runs on 11 different days. Measurements for evaluation of analytical performance were carried out with the same 
reversal of heparin binding
If results were Ͼ20% lower in heparin-plasma than in serum, samples were remeasured after pretreatment with Hepzyme (Dade Behring). Hepzyme is a lyophilized preparation of purified bacterial heparinase 1 (EC 4.2.2.7) that cleaves the heparin molecule at multiple sites (6 ) . Heparin degradation was carried out according to the manufacturer's instruction. Briefly, a sample of frozen (Ϫ70°C) heparin-plasma was brought to 37°C in a water bath. After complete thawing, the sample was recentrifuged at 3000g for 10 min, and 1 mL of the plasma was sequentially neutralized by dissolving lyophilized purified bacterial heparinase 1 in the sample. Samples were incubated at room temperature for 15 min, and measurements were carried out immediately after incubation.
measurement of aPTT
To evaluate the influence of therapeutic or bolus doses of heparin on troponin concentrations in heparin-plasma, the aPTT was measured and compared with the difference in results for heparin-plasma. The aPTT was determined automatically on an Amelung AMGA CS-400 coagulometer (Sigma Diagnostics) using Dade Actin FS activated PTT reagent (Dade Behring).
statistical analysis
The correlation between serum and plasma as well as the correlation between the two serum measurements was evaluated by the statistical procedure developed by Passing and Bablock (7 ). The percentage difference was evaluated by the Bland-Altman method (8 ) , as modified by Pollock et al. (9 ) . This procedure involves plotting the mean of the results for serum and heparin-plasma on the x axis against the percentage difference of both results (% relative difference) on the y axis.
Spearman correlation coefficients for comparisons of aPTT values with differences in results between heparinplasma and serum were calculated by a commercially available computer program (SPSS 7.5 for Windows; SPSS).
Results
The imprecision data for all three analytical test systems are summarized in Table 1 . Generally, at comparable relative concentrations the imprecision of the Roche Elecsys cTnT assay was twofold lower than the imprecision of the Abbott AxSYM cTnI method or the Bayer ACS:Centaur cTnI method.
A total of 100 serum and corresponding plasma sam- Table 1 . Within-run and between-day imprecision of the AxSYM, ACS:Centaur, and Elecsys troponin assays. 
Grouped-pair analysis and Bland-Altman difference plots revealed samples with results Ͼ20% lower in heparin-plasma than in serum in all three assays: 11% of all results on the ACS:Centaur; 9% of all results on the Elecsys; and 2% of all results on the AxSYM. Results are shown in detail in Table 2 and Fig. 2 . For the Abbott AxSYM cTnI assay, only two samples with concentrations near the detection limits were detected. Because differences in results between heparin-plasma and serum at such low concentrations might be affected by the higher imprecision of the analytical system and might also be clinically without any relevance, we excluded cases with results near the detection limit (Յ0.50 g/L for the AxSYM; Յ0.40 g/L for the ACS:Centaur; and Յ0.05 g/L for the Elecsys) from further data analysis. Table 3 lists all samples with results Ͼ20% lower in heparinplasma than in serum of the total of 100 samples tested. As shown, the lower results were confined to individual samples and mostly to only one test system. For the Elecsys cTnT assay, the difference in results affected only samples well above the clinical cutoff value for acute myocardial infarction. We could identify two samples with differences Ͼ40% (samples 2 and 8) that were from patients in the acute phase of myocardial infarction (Ͻ12 h after onset of chest pain). Of the remaining six samples, four were from the group of patients after open heart surgery, whereas two samples were from patients in the subacute phase of myocardial infarction (Ͼ12 h after onset of chest pain).
For the Bayer ACS:Centaur cTnI assay, the difference in results was mainly concentration dependent, with the largest differences in the lower concentration range. All affected samples except one were from patients with suspected or diagnosed acute coronary syndrome.
Values for the aPTT ranged from 24 s to Ͼ150 s (median, 45 s). For all three test systems, no correlation could be detected between the aPTT and troponin results in heparin-plasma (corresponding r S ϭ 0.015, Ϫ0.091, and Ϫ0.154 for the Abbott AxSYM, ACS:Centaur, and Elecsys, respectively), assuming that for the investigated patients there was no additional influence of therapeutic heparin concentrations or bolus doses of heparin on the troponin results in heparin-plasma.
To further clarify, if a lower result was caused by an in vitro heparin influence, the affected samples were remeasured after pretreatment with heparinase. The results are shown in Table 4 . After treatment with heparinase, the heparin-plasma/serum ratios for cTnT, which had been 34 -78%, were now 83-101%. In contrast to cTnT, the cTnI results obtained by the Bayer ACS:Centaur were worse after treatment with heparinase.
Serum results obtained after a second centrifugation were 0.30 -650.13 g/L for the AxSYM, 0.15-595.51 g/L for the ACS:Centaur, and 0.010 -18.340 g/L for the Elecsys. Comparison of results between the two serum measurements by Passing-Bablock regression analysis re- a Only samples with results Ͼ20% lower in heparin-plasma than in serum (out of total number of samples investigated; n ϭ 100) are included. In the other 78 samples, no difference Ͼ20% was detected. The mean results in serum (Ϯ 95% confidence interval) after centrifugation compared with the initial serum result were: 101% Ϯ 2% (AxSYM cTnI), 98% Ϯ 1% (ACS:Centaur cTnI), and 103% Ϯ 2% (Elecsys cTnT). None of the results obtained after the second centrifugation were Ͼ20% lower than the initial result for the same serum sample.
Discussion
Cardiac troponins are sensitive and reliable markers of damaged cardiac tissue and are therefore widely used in clinical practice. The existence of different cTnI assays with a wide variety of cutoff values as well as discrepancies between the results obtained by different methods are confusing (10 ). Adding to this confusion are reports of falsepositive results, caused by either heterophilic antibodies (11, 12 ) or incomplete separation of serum (1, 13 ) , that seem to affect some of the commercially available troponin assays.
Most patients with cardiac disease are anticoagulated during hospitalization. When serum is collected, full clot retraction from tubes without preservatives can take up to 15 min (2 ). Clots can continue to form even after the sample has been centrifuged and the serum is placed into the analytical instrument. When this occurs, the instrument can be blocked by fibrinous material, which leads to a flagged sample run. This will delay analysis, because of the additional time needed for recentrifugation and reanalysis of the sample, but will not lead to an erroneous result. On the other hand, small amounts of fibrin can cause nonspecific binding of the antibody, producing falsely increased troponin results without any flagging by the test instrument (1 ). In our study, we did not detect any increased troponin concentrations attributable to incomplete separation of serum, assuming that the total incidence is Ͻ1% of all tested samples.
Nevertheless, many laboratories prefer plasma rather than serum to shorten turnaround time. In addition, the National Academy of Clinical Biochemistry recommends the use of plasma as the specimen of choice for stat analysis of cardiac markers (2 ), but some analytical systems have the limitation that plasma anticoagulated with heparin, sodium citrate, or EDTA cannot be used because of random or systematic deviations (3 ). For EDTA tubes, troponin released as a ternary (cTnT-I-C) or binary (cTnI-C) complex will degrade to free subunits because the ionized calcium needed to maintain this complex is removed by chelation of the metal ions (14 ) . Troponin assays that do not exhibit an equimolar response between complexed and free subunits will produce significant biases between serum and EDTA-plasma. Heparin is not believed to disrupt complexes and therefore is unlikely to cause differences in results between serum and plasma (2 ) .
Many laboratories have relied on heparin-plasma for rapid determination of cTnT, as have several clinical studies, including the PRISM trial (5 ) . A recent study by Gerhardt et al. (4 ) published in this journal demonstrated that results obtained with heparin-plasma are 15% lower than those obtained with serum. On the basis of those results, Roche Diagnostics, manufacturer of the cTnT assay, strongly advised customers not to use heparinplasma in their assay. In contrast to the findings by Gerhardt et al. (4 ) , in our study the mean cTnT result for heparin-plasma was 99% of the value obtained for serum. Nevertheless, in 9 of 100 tested samples, the result for heparin-plasma was Ͼ20% lower that the result for serum, independent of the absolute cTnT concentration. A possible explanation for these obvious discrepancies might be the use of different blood collection systems with different heparin concentrations. In contrast to the study by Gerhardt et al. (4 ) , we used only one type of lithium heparinate tube, with a total heparin concentration of 15 IU/mL of whole blood (20 -30 IU/mL of plasma), whereas Gerhardt et al. used tubes with higher heparin concentrations. The results of both studies thus might not be directly comparable. In addition, a different selection of patients might have influenced the results of both studies. Because Gerhardt et al. (4 ) included mainly patients in the acute phase of myocardial infarction, the different distribution of cTnT isoforms in the early vs the late phase of myocardial infarction may explain the differences.
An effect of therapeutic heparin concentrations (usually ϳ1 IU/mL in patients with acute myocardial infarction) seems unlikely, considering the large amount of heparin (ϳ25 IU/mL of plasma) in the sampling tubes (15 ) . This is also supported by the lack of correlation between the aPTT as an equivalent for therapeutic heparin concentrations and loss of troponin recovery in heparin-plasma.
In our study, treatment with heparinase reversed the differences between heparin-plasma and serum seen in the Elecsys cTnT assay but had no influence on measurements on the Bayer ACS:Centaur. This implies, in combination with the concentration-dependent differences for the Bayer test, that in this case the lower result is more likely the effect of higher imprecision than the direct influence of heparin on the cTnI molecule detected by this assay. For cTnT, the lower results obtained for heparin-plasma could be explained by conformational changes of the antigen induced by direct interactions between the positively charged (pI 5.1) cTnT molecule and the negatively charged heparin. Such complexes can interfere with the antibody-antigen interaction, as shown previously by Katrukha et al. (16 ) .
In this study, we demonstrated that the use of heparin as an in vitro anticoagulant at a total concentration of 15 IU/mL of whole blood leads to significant biases in at least two of the investigated assays because of a certain percentage of samples with lower results compared with serum measurements. Therefore, at present we cannot recommend the use of heparin-plasma for determination of cardiac troponins for at least two of the investigated assays. The lower results obtained for heparin-plasma may affect clinical decisions or risk stratification in patients with suspected acute coronary syndrome. No influence of incomplete separation of serum on troponin concentrations could be detected in our patient cohort.
Additional studies are needed to clarify the exact mechanism by which heparin as an in vitro anticoagulant causes such interactions and why they are confined to individual samples. The manufacturers of cardiac troponin assays should be aware of this potential problem and work on the elimination of this interference. Other commercially available assays for determination of cardiac troponins, including bedside tests, should be checked for a possible disturbance by heparin-plasma.
